Genomic Epidemiology of SARS-CoV-2 Infection During the Initial Pandemic Wave | Infectious Diseases | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Genomic Epidemiology of SARS-CoV-2 Infection During the Initial Pandemic Wave and Association With Disease Severity

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME
Key Points

Question  Are SARS-CoV-2 variants, virus clades, or clade groups associated with disease severity and patient outcomes?

Findings  In this cross-sectional study of 302 SARS-CoV-2 isolates, 6 different Global Initiative on Sharing All Influenza Data clades circulated in the community followed by a rapid reduction in clade diversity. Several variants, including 23403A>G (D614G), were significantly associated with lower hospitalization rates and increased patient survival.

Meaning  These findings suggest that SARS-CoV-2 clade assignment is an important factor that may aid in estimating patient outcomes.

Abstract

Importance  Understanding of SARS-CoV-2 variants that alter disease outcomes are important for clinical risk stratification and may provide important clues to the complex virus-host relationship.

Objective  To examine the association of identified SARS-CoV-2 variants, virus clades, and clade groups with disease severity and patient outcomes.

Design, Setting, and Participants  In this cross-sectional study, viral genome analysis of clinical specimens obtained from patients at the Cleveland Clinic infected with SARS-CoV-2 during the initial wave of infection (March 11 to April 22, 2020) was performed. Identified variants were matched with clinical outcomes. Data analysis was performed from April to July 2020.

Main Outcomes and Measures  Hospitalization, intensive care unit (ICU) admission, mortality, and laboratory outcomes were matched with SARS-CoV-2 variants.

Results  Specimens sent for viral genome sequencing originated from 302 patients with SARS-CoV-2 infection (median [interquartile range] age, 52.6 [22.8 to 82.5] years), of whom 126 (41.7%) were male, 195 (64.6%) were White, 91 (30.1%) required hospitalization, 35 (11.6%) needed ICU admission, and 17 (5.6%) died. From these specimens, 2531 variants (484 of which were unique) were identified. Six different SARS-CoV-2 clades initially circulated followed by a rapid reduction in clade diversity. Several variants were associated with lower hospitalization rate, and those containing 23403A>G (D614G Spike) were associated with increased survival when the patient was hospitalized (64 of 74 patients [86.5%] vs 10 of 17 patients [58.8%]; χ21 = 6.907; P = .009). Hospitalization and ICU admission were similar regardless of clade. Infection with Clade V variants demonstrated higher creatinine levels (median [interquartile range], 2.6 [−0.4 to 5.5] mg/dL vs 1.0 [0.2 to 2.2] mg/dL; mean creatinine difference, 2.9 mg/dL [95% CI, 0.8 to 5.0 mg/dL]; Kruskal-Wallis P = .005) and higher overall mortality rates (3 of 14 patients [21.4%] vs 17 of 302 patients [5.6%]; χ21 = 5.640; P = .02) compared with other variants. Infection by strains lacking the 23403A>G variant showed higher mortality in multivariable analysis (odds ratio [OR], 22.4; 95% CI, 0.6 to 5.6; P = .01). Increased variants of open reading frame (ORF) 3a were associated with decreased hospitalization frequency (OR, 0.4; 95% CI, 0.2 to 0.96; P = .04), whereas increased variants of Spike (OR, 0.01; 95% CI, <0.01 to 0.3; P = .01) and ORF8 (OR, 0.03; 95% CI, <0.01 to 0.6; P = .03) were associated with increased survival.

Conclusions and Relevance  Within weeks of SARS-CoV-2 circulation, a profound shift toward 23403A>G (D614G) specific genotypes occurred. Replaced clades were associated with worse clinical outcomes, including mortality. These findings help explain persistent hospitalization yet decreasing mortality as the pandemic progresses. SARS-CoV-2 clade assignment is an important factor that may aid in estimating patient outcomes.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Accepted for Publication: March 7, 2021.

Published: April 26, 2021. doi:10.1001/jamanetworkopen.2021.7746

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Esper FP et al. JAMA Network Open.

Corresponding Author: Frank P. Esper, MD, Center for Pediatric Infectious Disease, Cleveland Clinic Children’s, 9500 Euclid Ave, R3, Cleveland, OH 44195 (esperf@ccf.org).

Author Contributions: Dr Esper had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Rubin and J. Li are co–senior authors.

Concept and design: Esper, Cheng, Adhikari, Farkas, Procop, Chan, Rubin, J. Li.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Esper, Adhikari, Farkas, Chan, J. Li.

Critical revision of the manuscript for important intellectual content: Esper, Cheng, Tu, D. Li, E. Li, Farkas, Procop, Ko, Chan, Jehi, Rubin, J. Li.

Statistical analysis: Esper, Adhikari, D. Li, E. Li, J. Li.

Obtained funding: Esper, Chan, Jehi, Rubin, J. Li.

Administrative, technical, or material support: Cheng, Adhikari, Tu, Farkas, Procop, Ko, Chan, Jehi, Rubin.

Supervision: Cheng, Farkas, Chan, Rubin, J. Li.

Conflict of Interest Disclosures: Dr Esper reported receiving personal fees from MSL Group for serving as an advisory board member outside the submitted work. Dr Cheng reported receiving grants from the National Cancer Institute and personal fees from GLG Consulting, Putnam Associates, and Health Advances outside the submitted work. Dr Adhikari reported receiving grants from National Science Foundation outside the submitted work. Dr Chan reported receiving stock from Gritstone Oncology, personal fees from NysnoBio, and grants from Pfizer, Illumina, and AstraZeneca outside the submitted work. No other disclosures were reported.

Funding/Support: This project was supported in part by National Science Foundation grants IIS-2027667 (to Drs J. Li and Esper), CCF-2006780 (to Dr J. Li), CCF-1815139 (to Dr J. Li), and NS097719 (to Dr J. Li), and through unrestricted funds from the Robert J. Tomsich Pathology and Laboratory Medicine Institute.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: Yamini Mandelia, MD (Department of Pediatrics, East Carolina University), and Lihui Yin, PhD, and Maureen Jakubowski, BS (Department of Molecular Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute), provided excellent assistance in patient identification and virus genome sequencing. No compensation was provided for their assistance.

References
1.
Centers for Disease Control and Prevention. COVID data tracker. Accessed November 20, 2020. https://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscases
2.
Stokes  EK , Zambrano  LD , Anderson  KN ,  et al.  Coronavirus Disease 2019 Case Surveillance—United States, January 22-May 30, 2020.   MMWR Morb Mortal Wkly Rep. 2020;69(24):759-765. doi:10.15585/mmwr.mm6924e2PubMedGoogle ScholarCrossref
3.
Worobey  M , Pekar  J , Larsen  BB ,  et al.  The emergence of SARS-CoV-2 in Europe and the US.   bioRxiv. Published online May 23, 2020. doi:10.1101/2020.05.21.109322PubMedGoogle Scholar
4.
Horwitz  LI , Jones  SA , Cerfolio  RJ ,  et al.  Trends in COVID-19 risk-adjusted mortality rates.   J Hosp Med. 2021;16(2):90-92. doi:10.12788/jhm.3552PubMedGoogle ScholarCrossref
5.
Bhimraj  A , Morgan  RL , Shumaker  AH ,  et al.  Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19.   Clin Infect Dis. Published online April 27, 2020. doi:10.1093/cid/ciaa478PubMedGoogle Scholar
6.
Pan  H , Peto  R , Henao-Restrepo  AM ,  et al; WHO Solidarity Trial Consortium.  Repurposed antiviral drugs for Covid-19: interim WHO Solidarity Trial results.   N Engl J Med. 2021;384(6):497-511. doi:10.1056/NEJMoa2023184PubMedGoogle ScholarCrossref
7.
Long  SW , Olsen  RJ , Christensen  PA ,  et al  Molecular architecture of early dissemination and massive second wave of the SARS-CoV-2 virus in a major metropolitan area.   mBio. 2020;11(6):e02707-20. doi:10.1128/mbio.02707-20Google Scholar
8.
Rambaut  A , Holmes  EC , O’Toole  Á ,  et al.  A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology.   Nat Microbiol. 2020;5(11):1403-1407. doi:10.1038/s41564-020-0770-5PubMedGoogle ScholarCrossref
9.
Brufsky  A .  Distinct viral clades of SARS-CoV-2: implications for modeling of viral spread.   J Med Virol. 2020;92(9):1386-1390. doi:10.1002/jmv.25902PubMedGoogle ScholarCrossref
10.
Guan  Q , Sadykov  M , Mfarrej  S ,  et al.  A genetic barcode of SARS-CoV-2 for monitoring global distribution of different clades during the COVID-19 pandemic.   Int J Infect Dis. 2020;100:216-223. doi:10.1016/j.ijid.2020.08.052PubMedGoogle ScholarCrossref
11.
Shu  Y , McCauley  J .  GISAID: Global initiative on sharing all influenza data: from vision to reality.   Euro Surveill. 2017;22(13):30494. doi:10.2807/1560-7917.ES.2017.22.13.30494PubMedGoogle ScholarCrossref
12.
Korber  B , Fischer  WM , Gnanakaran  S ,  et al.  Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus.   Cell. 2020;182(4):812-827.e19. doi:10.1016/j.cell.2020.06.043PubMedGoogle ScholarCrossref
13.
Volz  E , Hill  V , McCrone  JT ,  et al.  Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity.   Cell. 2021;184(1):64-75.e11. doi:10.1016/j.cell.2020.11.020PubMedGoogle ScholarCrossref
14.
Jehi  L , Ji  X , Milinovich  A ,  et al.  Individualizing risk prediction for positive coronavirus disease 2019 testing: results from 11,672 patients.   Chest. 2020;158(4):1364-1375. doi:10.1016/j.chest.2020.05.580PubMedGoogle ScholarCrossref
15.
von Elm  E , Altman  DG , Egger  M , Pocock  SJ , Gøtzsche  PC , Vandenbroucke  JP ; STROBE Initiative.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.   J Clin Epidemiol. 2008;61(4):344-349. doi:10.1016/j.jclinepi.2007.11.008PubMedGoogle ScholarCrossref
16.
Centers of Disease Control and Prevention. CDC 2019: novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel. Published December 1, 2020. Accessed March 25, 2021. https://www.fda.gov/media/134922/download
17.
Garrison  E , Marth  G . Haplotype-based variant detection from short-read sequencing.  arXiv. Published July 20, 2012. Accessed March 25, 2021. https://arxiv.org/abs/1207.3907v2
18.
Katoh  K , Rozewicki  J , Yamada  KD .  MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization.   Brief Bioinform. 2019;20(4):1160-1166. doi:10.1093/bib/bbx108PubMedGoogle ScholarCrossref
19.
Hadfield  J , Megill  C , Bell  SM ,  et al.  NextStrain: real-time tracking of pathogen evolution.   Bioinformatics. 2018;34(23):4121-4123. doi:10.1093/bioinformatics/bty407PubMedGoogle ScholarCrossref
20.
GISAID. Global initiative on sharing all influenza data. Accessed March 25, 2021. https://www.gisaid.org/
21.
Seabold  S , Perktold  J . Statsmodels: econometric and statistical modeling with Python. Published 2010. Accessed March 25, 2021. https://conference.scipy.org/proceedings/scipy2010/seabold.html
22.
Pedregosa  F , Varoquaux  G , Gramfort  A ,  et al.  Scikit-learn: machine learning in Python.   J Machine Learning Res. 2011;12(85):2825-2830. Accessed March 25, 2021. https://www.jmlr.org/papers/volume12/pedregosa11a/pedregosa11a.pdfGoogle Scholar
23.
Wang  R , Chen  J , Gao  K , Hozumi  Y , Yin  C , Wei  G . Characterizing SARS-CoV-2 mutations in the United States.  Res Sq. Published August 11, 2020. doi:10.21203/rs.3.rs-49671/v1PubMed
24.
Ortiz-Prado  E , Simbaña-Rivera  K , Gómez-Barreno  L ,  et al.  Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the coronavirus disease 2019 (COVID-19), a comprehensive literature review.   Diagn Microbiol Infect Dis. 2020;98(1):115094. doi:10.1016/j.diagmicrobio.2020.115094PubMedGoogle Scholar
25.
Ahmadpour  D , Ahmadpoor  P , Rostaing  L .  Impact of circulating SARS-CoV-2 mutant G614 on the COVID-19 pandemic.   Iran J Kidney Dis. 2020;14(5):331-334.PubMedGoogle Scholar
26.
Young  BE , Fong  SW , Chan  YH ,  et al.  Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study.   Lancet. 2020;396(10251):603-611. doi:10.1016/S0140-6736(20)31757-8PubMedGoogle ScholarCrossref
27.
Nakamichi  K , Shen  JZ , Lee  CS ,  et al.  Outcomes associated with SARS-CoV-2 viral clades in COVID-19.   medRxiv. Published September 25, 2020. doi:10.1101/2020.09.24.20201228Google Scholar
28.
Pandey  U , Yee  R , Shen  L ,  et al.  High prevalence of SARS-CoV-2 genetic variation and D614G mutation in pediatric patients with COVID-19.   Open Forum Infect Dis. Published online November 13, 2020. doi:10.1093/ofid/ofaa551Google Scholar
29.
Puenpa  J , Suwannakarn  K , Chansaenroj  J ,  et al.  Molecular epidemiology of the first wave of severe acute respiratory syndrome coronavirus 2 infection in Thailand in 2020.   Sci Rep. 2020;10(1):16602. doi:10.1038/s41598-020-73554-7PubMedGoogle ScholarCrossref
30.
Laha  S , Chakraborty  J , Das  S , Manna  SK , Biswas  S , Chatterjee  R .  Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission.   Infect Genet Evol. 2020;85:104445. doi:10.1016/j.meegid.2020.104445PubMedGoogle Scholar
31.
Zhang  L , Jackson  CB , Mou  H ,  et al  The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity.   bioRxiv. Published June 12, 2020. doi:10.1101/2020.06.12.148726Google Scholar
32.
Ogawa  J , Zhu  W , Tonnu  N ,  et al.  The D614G mutation in the SARS-CoV2 Spike protein increases infectivity in an ACE2 receptor dependent manner.   bioRxiv. Published July 22, 2020. doi:10.1101/2020.07.21.214932Google Scholar
33.
Korber  B , Fischer  WM , Gnanakaran  S ,  et al; Sheffield COVID-19 Genomics Group.  Evidence that D614G increases infectivity of the COVID-19 virus.   Cell. 2020;182(4):812-827.e19. doi:10.1016/j.cell.2020.06.043Google ScholarCrossref
34.
Pujadas  E , Chaudhry  F , McBride  R ,  et al.  SARS-CoV-2 viral load predicts COVID-19 mortality.   Lancet Respir Med. 2020;8(9):e70. doi:10.1016/S2213-2600(20)30354-4PubMedGoogle Scholar
35.
Fajnzylber  J , Regan  J , Coxen  K ,  et al; Massachusetts Consortium for Pathogen Readiness.  SARS-CoV-2 viral load is associated with increased disease severity and mortality.   Nat Commun. 2020;11(1):5493. doi:10.1038/s41467-020-19057-5PubMedGoogle ScholarCrossref
36.
Wang  R , Chen  J , Hozumi  Y , Yin  C , Wei  GW .  Decoding asymptomatic COVID-19 infection and transmission.   J Phys Chem Lett. 2020;11(23):10007-10015. doi:10.1021/acs.jpclett.0c02765PubMedGoogle ScholarCrossref
37.
Gupta  AM , Chakrabarti  J , Mandal  S .  Non-synonymous mutations of SARS-CoV-2 leads epitope loss and segregates its variants.   Microbes Infect. 2020;22(10):598-607. doi:10.1016/j.micinf.2020.10.004PubMedGoogle ScholarCrossref
38.
Wu  S , Tian  C , Liu  P ,  et al.  Effects of SARS-CoV-2 mutations on protein structures and intraviral protein-protein interactions.   J Med Virol. 2021;93(4):2132-2140. doi:10.1002/jmv.26597PubMedGoogle ScholarCrossref
39.
Patel  SK , Singh  R , Rana  J ,  et al.  The kidney and COVID-19 patients: important considerations.   Travel Med Infect Dis. 2020;37:101831. doi:10.1016/j.tmaid.2020.101831PubMedGoogle Scholar
40.
Gabarre  P , Dumas  G , Dupont  T , Darmon  M , Azoulay  E , Zafrani  L .  Acute kidney injury in critically ill patients with COVID-19.   Intensive Care Med. 2020;46(7):1339-1348. doi:10.1007/s00134-020-06153-9PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close